Durvalumab Remodels Immune Microenvironment but Rarely Achieves pCR in Stage I TNBC

The POP-DURVA study demonstrates that two doses of durvalumab quickly alter the immune microenvironment in patients with stage I triple-negative breast cancer (TNBC). Despite increased tumor-infiltrating lymphocytes (TILs) and PD-L1 expression, pathological complete response (pCR) remains uncommon.

Originally published by gnews